Media Hub

KeyScreen® GI Parasite PCR 

Stay Ahead of Parasites with Diagnostically Superior Screening.

In a recent study comparing KeyScreen® GI Parasite PCR to O&P testing, KeyScreen detected >3X more Giardia while indicating zoonotic potential.1 

KeyScreen® GI Parasite PCR gives you the power to detect Giardia while also differentiating Giardia strains with zoonotic potential. This allows you to not only make clinical management decisions for pets, but also assist in pet-owner conversations, along with supporting these communications in the most vulnerable groups, such as children, pregnant women, the elderly, and the immunocompromised. 

This algorithm guides you through: 

  • Fecal testing 
  • Management/treatment 
  • Persistent Giardia cases 

Risk assessment for zoonotic potential 

Download the Giardia algorithm here 

Parasites are adapting, expanding, and emerging across the U.S. and Canada. Traditional fecal testing has limitations and advanced diagnostics are needed to meet needs and inform risk. 

KeyScreen provides comprehensive screening detection to help you meet today’s dog, cat, and pet owner prevention and treatment needs — including the ability to detect and differentiate one type of parasite from another. For example, the tapeworm Echinococcus multilocularis cannot be differentiated from Taenia without PCR and is a rising One Health concern.3 

KeyScreen goes beyond simple testing. It provides fecal surveillance that allows dogs to act as sentinels for human risk through detection and differentiation of parasites — as described in a recent collaborative study which adds to the growing body scientific information on tapeworm parasites.3 

Through the power of big data fecal surveillance, and individual dog and cat cases that come into clinics, KeyScreen is making innovative peer-reviewed science accessible and affordable. This clinically relevant research on parasite frequencies, emergence, and evolution helps you raise risk awareness, talk fecal testing, and inform prevention for your pet owners.  

At Antech, we are committed to supporting veterinary teams because we know that the health and wellness of pets and pet owners are key to everything you do. And that’s true for us, too. 

KeyScreen® GI Parasite PCR is the only way to stay a step ahead of mutating parasites.4-7 

Drug-resistant hookworm infections have been reported in more than 70 dog breeds.4,5 1 in 10 (11.2%) samples from U.S. dogs with A. caninum infection contained the genetic markers for benzimidazole resistance.4 And that’s just in the U.S. Of the Canada dogs with A. caninum infection, 1 in 25 (4.1 %) samples contained the genetic markers for benzimidazole resistance.7 

  • The only screening panel in veterinary medicine that can detect benzimidazole-resistant hookworms  
  • Demonstrated a 1.4x greater A. caninum detection rate compared to O&P7  

Start using superior GI screening today. 

The KeyScreen GI Parasites PCR Panel now has 12 peer-reviewed publications. This paper1 compares KeyScreen to O&P’s done at a veterinary reference lab, concluding that KeyScreen is diagnostically superior.  

KeyScreen also provided information that went beyond traditional fecal O&P, such as detecting parasites that O&P did not, along with markers important for clinical management and pet-owner communication — like hookworm treatment resistance, and Giardia with zoonotic potential, both Canadian concerns. 

KeyScreen leverages the power of molecular diagnostics (PCR) to detect genetic traces of parasites. With this routine wellness screening PCR test, you find parasite infection in the pets you care for that a microscopic exam can’t. 

Hookworms are complex to manage, more prevalent than we thought, and they’ve recently developed drug resistance to our most common treatments. These benzimidazole (e.g.,fenbendazole, febantel) treatment resistant hookworms have recently been found to be widespread throughout the U.S. and are now endemic in Canada.4,7 

A recent study7 using KeyScreen described a series of dogs in different parts of Canada, that were not from the U.S., with the marker for hookworm benzimidazole treatment resistance. 

KeyScreen now contains two types of benzimidazole resistance markers within the parasite PCR test panel in order to broaden fecal detection and awareness of the hookworm A. caninum’s rapidly emerging antimicrobial-anthelmintic resistance. This advanced molecular detection innovation provides veterinary teams with help for treatment selection on this evolving One Health concern and assists with pet owner communication to protect pets, people, and the environment (pick up the poop, please!). 

Otis: 4-month-old intact male Bullmastiff  

Location: Ontario, Canada  

Background: Otis lives outside of the city; he has never traveled to the U.S., hasn’t had any exposure to other dogs, and has never been at a kennel for boarding.  

Read all about Otis’ diagnosis, treatment, and results in this case study. 

For veterinarians seeking to ensure positive health outcomes for pets, their families, and the broader pet community, you can find more GI parasites and treat them with precision, speed, and confidence.    

  • Screens for 20 intestinal parasites 
  • Detects 2x more infections1 when compared to in-house fecal flotations (O&P) 
  • Detects benzimidazole resistance in hookworms 

Determines the zoonotic potential of Giardia 


*Explore our full list of references and studies here

REFERENCES: 

1. Leutenegger CM, et al. Comparative Study of a Broad qPCR Panel and Centrifugal Flotation for Detection of Gastrointestinal Parasites in Fecal Samples from Dogs and Cats in the United States. Parasites & Vectors. 2023, https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-023-05904-z 

2. Leutenegger CM, et al. Frequency of intestinal parasites in dogs and cats identified by molecular diagnostics. ACVIM abstract, Philadelphia, June 2023. 

3. Evason MD, et al. Novel molecular diagnostic (PCR) diagnosis and outcome of intestinal Echinococcus multilocularis in a dog from western Canada. JAVMA May 2023:1-3. https://avmajournals.avma.org/view/journals/javma/aop/javma.23.03.0179/javma.23.03.0179.xml 

4. Leutenegger CM, et al. Screening for the Ancylostoma caninum Benzimidazole resistance marker F167Y reveals widespread, geographic, seasonal, age and breed distribution in North America. February 2024, available online. https://www.sciencedirect.com/science/article/pii/S2211320724000010 

5. Hook before you treat! Drug-resistant Hookworms in North America, January 2024, Leutenegger, Evason. TVP-NAVC. https://todaysveterinarypractice.com/parasitology/drug-resistant-hookworms-in-north-america/ 

6. Leutenegger CM, et al. Emergence of Ancylostoma caninum parasites with the benzimidazole resistance F167Y polymorphism in the US dog population. Int. J. Parasitol. Drugs Drug Resist.2023;14:131-140. 

7. Evason, MD, et al. Emergence of canine hookworm treatment resistance: Novel detection of Ancylostoma caninum anthelmintic resistance markers by fecal PCR in 11 dogs from Canada, Am J Vet Res (published online ahead of print 2023): https://doi.org/10.2460/ajvr.23.05.0116 

8. Evason M, DeBess E, Culwell N, Ogeer J, Culwell N, Leutenegger CM. Hookworm anthelmintic resistance: Novel fecal PCR Ancylostoma caninum benzimidazole resistance marker detection in a dog. JAAHA. March/April 2024. https://meridian.allenpress.com/jaaha/article-abstract/60/2/87/499140/Hookworm-Anthelmintic-Resistance-Novel-Fecal?redirectedFrom=fulltext 

9. Leutenegger CM, et al. Association of the novel benzimidazole resistance marker Q134H with F167Y in dogs with Ancylostoma caninum. ACVIM abstract, Philadelphia June 2023. 

Share

Read More Articles

×